Novartis (NOVN) Given a CHF 83 Price Target at Morgan Stanley

Morgan Stanley set a CHF 83 price objective on Novartis (VTX:NOVN) in a research report sent to investors on Thursday morning, Borsen Zeitung reports. The brokerage currently has a sell rating on the stock.

A number of other equities research analysts have also issued reports on NOVN. Jefferies Financial Group set a CHF 105 target price on shares of Novartis and gave the stock a buy rating in a report on Wednesday, January 30th. UBS Group set a CHF 85 target price on shares of Novartis and gave the stock a neutral rating in a report on Wednesday, January 30th. Kepler Capital Markets set a CHF 94 target price on shares of Novartis and gave the stock a buy rating in a report on Wednesday, January 30th. Deutsche Bank set a CHF 96 target price on shares of Novartis and gave the stock a neutral rating in a report on Wednesday, January 30th. Finally, Credit Suisse Group set a CHF 86 target price on shares of Novartis and gave the stock a neutral rating in a report on Thursday, January 31st. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and eight have issued a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus price target of CHF 89.06.

Novartis has a 1-year low of CHF 72.45 and a 1-year high of CHF 88.30.

About Novartis

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

Further Reading: What is a growth and income fund?

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.